Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2015, Vol. 20 ›› Issue (1): 106-111.

Previous Articles     Next Articles

Progress on researches for topotecan in combination drug therapy

ZHANG Zhe, SUN Li, YUAN Sheng-tao   

  1. Jiangsu Center for Drug Screening, China Pharmaceutical University, Nanjing 210009, Jiangsu, China
  • Received:2013-11-25 Revised:2014-10-07 Published:2020-07-20

Abstract: Malignant neoplasm threats people’s health seriously and draws wide attention of the scholars. Topotecan (TPT), a topoisonerase inhibitor, can induce the fragmentation of DNA replication fork, therefore it is not easy to produce drug resistance. Also topotecan has been widely and efficiently used in the treatment of ovarian carcinoma and small cell lung carcinoma. TPT has exhibited certain antitumor synergistic effect by combining with a variety of compounds, such as platinum, sorafini, bevacizumab, amrubicin, pemetrexed, gemcitabine. Therefore, it is worthy to investigate the applications of topotecan in combination drug therapy.

Key words: topotecan, tumor, combination drug therapy

CLC Number: